Fujian Wanchen Biotechnology Group Past Earnings Performance
Past criteria checks 2/6
Fujian Wanchen Biotechnology Group's earnings have been declining at an average annual rate of -46.2%, while the Food industry saw earnings growing at 2.5% annually. Revenues have been growing at an average rate of 82.4% per year. Fujian Wanchen Biotechnology Group's return on equity is 28.1%, and it has net margins of 0.2%.
Key information
-46.2%
Earnings growth rate
-50.2%
EPS growth rate
| Food Industry Growth | 7.2% |
| Revenue growth rate | 82.4% |
| Return on equity | 28.1% |
| Net Margin | 0.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Fujian Wanchen Biotechnology Group's (SZSE:300972) Strong Earnings Are Of Good Quality
Nov 04
Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company
Oct 01Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing
Sep 30We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt
Aug 04Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)
Jun 06Revenue & Expenses Breakdown
How Fujian Wanchen Biotechnology Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 25,006 | 58 | 1,889 | 4 |
| 30 Jun 24 | 17,992 | -76 | 1,481 | 4 |
| 31 Mar 24 | 13,362 | -129 | 1,158 | 4 |
| 31 Dec 23 | 9,294 | -83 | 876 | 3 |
| 30 Sep 23 | 5,091 | -46 | 536 | 3 |
| 30 Jun 23 | 2,564 | 40 | 277 | 2 |
| 31 Mar 23 | 1,194 | 76 | 112 | 2 |
| 01 Jan 23 | 549 | 48 | 52 | 2 |
| 30 Sep 22 | 546 | 82 | 29 | 1 |
| 30 Jun 22 | 471 | 38 | 25 | 2 |
| 31 Mar 22 | 448 | 25 | 26 | 2 |
| 01 Jan 22 | 435 | 23 | 25 | 2 |
| 30 Sep 21 | 371 | 4 | 25 | 2 |
| 30 Jun 21 | 399 | 33 | 24 | 0 |
| 31 Mar 21 | 417 | 65 | 22 | 0 |
| 31 Dec 20 | 450 | 96 | 22 | 0 |
| 30 Sep 20 | 449 | 101 | 23 | 0 |
| 30 Jun 20 | 460 | 110 | 24 | 0 |
| 31 Mar 20 | 483 | 130 | 24 | 0 |
| 31 Dec 19 | 451 | 92 | 24 | 0 |
| 30 Sep 19 | 442 | 82 | 40 | 0 |
| 30 Jun 19 | 418 | 74 | 24 | 0 |
| 31 Mar 19 | 358 | 28 | 28 | 0 |
| 01 Jan 19 | 343 | 35 | 23 | 0 |
| 30 Sep 18 | 298 | 15 | 18 | 0 |
| 30 Jun 18 | 258 | -3 | 19 | 0 |
| 31 Mar 18 | 265 | 24 | 18 | 0 |
| 01 Jan 18 | 247 | 16 | 18 | 0 |
| 30 Sep 17 | 259 | 31 | 5 | 0 |
| 30 Jun 17 | 267 | 46 | 16 | 0 |
| 31 Mar 17 | 254 | 52 | 11 | 0 |
| 31 Dec 16 | 220 | 39 | 14 | 0 |
| 30 Sep 16 | 189 | 40 | 14 | 0 |
| 30 Jun 16 | 157 | 30 | 14 | 0 |
| 31 Mar 16 | 157 | 31 | 14 | 0 |
| 31 Dec 15 | 157 | 33 | 14 | 0 |
| 30 Sep 15 | 149 | 30 | 11 | 0 |
| 30 Jun 15 | 160 | 37 | 12 | 0 |
| 31 Mar 15 | 145 | 35 | 11 | 0 |
| 31 Dec 14 | 130 | 34 | 11 | 0 |
Quality Earnings: 300972 has high quality earnings.
Growing Profit Margin: 300972 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300972's earnings have declined by 46.2% per year over the past 5 years.
Accelerating Growth: 300972 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300972 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Food industry (-5.8%).
Return on Equity
High ROE: Whilst 300972's Return on Equity (28.14%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 17:33 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fujian Wanchen Biotechnology Group Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wendan Wang | China International Capital Corporation Limited |
| Chenghui Xiong | Huatai Research |
| Junhao Fan | Huatai Research |